Wei Zhang

List of Publications by Year
in descending order

44 papers	15,139 citations	279487 23 h-index	264894 42 g-index
45 all docs	45 docs citations	45 times ranked	20259 citing authors

#	Article	IF	Citations
1	Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Cancer Science, 2022, 113, 756-769.	1.7	29
2	Integrated analysis of the prognostic and oncogenic roles of OPN3 in human cancers. BMC Cancer, 2022, 22, 187.	1.1	6
3	Development and Validation of a Novel Prognostic Model for Lower-Grade Glioma Based on Enhancer RNA-Regulated Prognostic Genes. Frontiers in Oncology, 2022, 12, 714338.	1.3	4
4	In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells. International Journal of Molecular Sciences, 2022, 23, 5691.	1.8	11
5	A novel DNA repair–related nomogram predicts survival in low–grade gliomas. CNS Neuroscience and Therapeutics, 2021, 27, 186-195.	1.9	7
6	Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2021, 499, 60-72.	3.2	194
7	Uronic acid metabolic process–related gene expression–based signature predicts overall survival of glioma. Bioscience Reports, 2021, 41, .	1.1	0
8	High–sensitive clinical diagnostic method for PTPRZ1–MET and the characteristic protein structure contributing to ligand–independent MET activation. CNS Neuroscience and Therapeutics, 2021, 27, 617-628.	1.9	7
9	Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells. OncoTargets and Therapy, 2021, Volume 14, 1707-1718.	1.0	12
10	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. Genomics, Proteomics and Bioinformatics, 2021, 19, 1-12.	3.0	439
11	A potentially effective drug for patients with recurrent glioma: sermorelin. Annals of Translational Medicine, 2021, 9, 406-406.	0.7	1
12	Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes. British Journal of Cancer, 2021, 125, 255-264.	2.9	9
13	neoDL: a novel neoantigen intrinsic feature-based deep learning model identifies IDH wild-type glioblastomas with the longest survival. BMC Bioinformatics, 2021, 22, 382.	1.2	3
14	Multiomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches. Frontiers in Genetics, 2021, 12, 741325.	1.1	0
15	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion. Frontiers in Immunology, 2021, 12, 800928.	2.2	6
16	Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages. Cancer Medicine, 2020, 9, 1955-1965.	1.3	10
17	A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. Scientific Reports, 2020, 10, 16218.	1.6	15
18	A novel methylation signature predicts radiotherapy sensitivity in glioma. Scientific Reports, 2020, 10, 20406.	1.6	5

#	Article	IF	Citations
19	Redox Regulator GLRX Is Associated With Tumor Immunity in Glioma. Frontiers in Immunology, 2020, 11, 580934.	2.2	17
20	Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis. Frontiers in Immunology, 2020, 11, 581209.	2.2	26
21	Molecular subtyping reveals immune alterations in <scp><i>IDH</i></scp> wildâ€type lowerâ€grade diffuse glioma. Journal of Pathology, 2020, 251, 272-283.	2.1	42
22	Classification of diffuse lowerâ€grade glioma based on immunological profiling. Molecular Oncology, 2020, 14, 2081-2095.	2.1	48
23	Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide. Cancers, 2020, 12, 3859.	1.7	20
24	<p>Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy</p>. OncoTargets and Therapy, 2019, Volume 12, 10263-10273.	1.0	25
25	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	6.6	3,706
26	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Reports, 2018, 23, 255-269.e4.	2.9	204
27	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. Cell Death and Disease, 2018, 9, 1190.	2.7	42
28	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell, 2018, 175, 1665-1678.e18.	13.5	250
29	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. OncoImmunology, 2017, 6, e1328339.	2.1	114
30	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. OncoImmunology, 2016, 5, e1196310.	2.1	176
31	CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2016, 375, 263-273.	3.2	448
32	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 2016, 164, 550-563.	13.5	1,695
33	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	13.9	2,582
34	Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathologica, 2015, 130, 587-597.	3.9	68
35	Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. Oncotarget, 2015, 6, 36643-36651.	0.8	39
36	A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3538-3543.	3.3	93

#	Article	IF	Citations
37	RNA-seq of 272 gliomas revealed a novel, recurrent *PTPRZ1-MET* fusion transcript in secondary glioblastomas. Genome Research, 2014, 24, 1765-1773.	2.4	316
38	Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas. Oncotarget, 2014, 5, 12593-12606.	0.8	36
39	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
40	Whole‐Genome mRNA Expression Profiling Identifies Functional and Prognostic Signatures in Patients with Mesenchymal Glioblastoma Multiforme. CNS Neuroscience and Therapeutics, 2013, 19, 714-720.	1.9	24
41	Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMPâ˜' primary glioblastoma. Cancer Letters, 2013, 328, 120-125.	3.2	61
42	Whole‐genome microRNA expression profiling identifies a 5‐microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer, 2013, 119, 814-824.	2.0	79
43	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro-Oncology, 2012, 14, 1432-1440.	0.6	163
44	Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China. PLoS ONE, 2012, 7, e30339.	1.1	114